The goal of the Harvard/MIT MD-PhD Program is to provide our students with a world-class educational experience that embraces an integration of compassionate medical care and breakthrough research to drive biomedical discovery and translation. We are laser-focused on creating an intellectually dynamic and nurturing community that enables our students to flourish, both personally and professionally, throughout their award period. This year?s Harvard Medical School curriculum revision has provided the MD-PhD program with an unprecedented opportunity to optimize the integration of MD and PhD education for our students, who benefit from two tracks, namely Pathways and Health, Sciences, and Technology (HST). Pathways features a large and diverse class whose backgrounds run the gamut of liberal arts education. The Pathways curriculum now starts with a 14 month intensive introduction to the essentials of medical education with prompt entry to the wards by October of Year 2. The HST program has a smaller class that emphasizes the science behind the medicine, focusing on mechanism, quantitation, and innovation. HST class work runs through March of Year 2, followed by the transition to the wards. Thus, all MD-PhD students now experience clinical responsibility prior to initiating their PhD studies, providing clinical insight that can influence their research direction and catalyze early career planning. This upfront clinical credit affords a new level of scheduling flexibility for re-entry to Year 3 of medical school after PhD completion, which should benefit the overall time-to-degrees. Our students have limitless options for PhD training in the basic, engineering, and social sciences across the campuses of Harvard Medical School, MIT, and all affiliated Boston hospitals and research institutes. Upon return from graduate school, the hospital experiences of Pathways and HST students are balanced with educational components that emphasize an intimate linkage between pathophysiology and patient relevance. Importantly, the MD-PhD program faculty and staff provide the academic, social, and administrative glue that brings our robust community of 181 students together. Led by Faculty Director, Loren Walensky, MD, PhD, and Administrative Director, Amy Cohen, our program is composed of key organizational components including a Board of Overseers, Faculty Leadership Council, Subcommittees on Academic Advising, Admissions, and Social Sciences, a Student Steering Committee, and Program Office Staff. Academic paracurricular offerings include our summer zero course, noon clinical case conferences, MD-PhD grand grounds, a clinical preceptorship program, transition bootcamps, meet- the-investigator series, and alumni career development mixers. To provide for a rich social environment, we also offer a summer barbecue, weekend long retreat on Cape Cod, a big sib program, ?dinners for 8?, MD-PhD breakfasts and happy hours, and a series of special events at faculty member homes. Under new leadership since 2013, the MD-PhD program has implemented a battery of programmatic changes designed to maximize the educational impact of MD-PhD training at Harvard and MIT.
The mission of the MD-PhD Program at Harvard and MIT is to train the next-generation of physician-scientist leaders who will intertwine premier clinical care and leading edge scientific investigation to deliver on the promise of new biomedical solutions to alleviate human suffering. By harnessing the academic, clinical, and research environments of Harvard Medical School, the Massachusetts Institute of Technology, and all affiliated Boston hospitals and research institutes, we aim to provide our students with unparalleled depth and breadth of clinical and research educational opportunities balanced by a profoundly caring and invested community of student colleagues and faculty mentors. Under new leadership since 2013, the program has undergone a comprehensive review of operations to both reinforce what works and institute a battery of educational, social, and administrative changes to make the Harvard/MIT training experience that much better, now and into the future.
|Rodin, Rachel E; Walsh, Christopher A (2018) Somatic Mutation in Pediatric Neurological Diseases. Pediatr Neurol 87:20-22|
|Sievers, Quinlan L; Petzold, Georg; Bunker, Richard D et al. (2018) Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362:|
|Rodan, Lance H; Hauptman, Marissa; D'Gama, Alissa M et al. (2018) Novel founder intronic variant in SLC39A14 in two families causing Manganism and potential treatment strategies. Mol Genet Metab 124:161-167|
|Gusev, Alexander; Mancuso, Nicholas; Won, Hyejung et al. (2018) Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights. Nat Genet 50:538-548|
|Lodato, Michael A; Rodin, Rachel E; Bohrson, Craig L et al. (2018) Aging and neurodegeneration are associated with increased mutations in single human neurons. Science 359:555-559|
|Short, Francesca L; Akusobi, Chidiebere; Broadhurst, William R et al. (2018) The bacterial Type III toxin-antitoxin system, ToxIN, is a dynamic protein-RNA complex with stability-dependent antiviral abortive infection activity. Sci Rep 8:1013|
|Miyamoto, David T; Lee, Richard J; Kalinich, Mark et al. (2018) An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. Cancer Discov 8:288-303|
|Kalinich, Mark; Haber, Daniel A (2018) Cancer detection: Seeking signals in blood. Science 359:866-867|
|Wutz, Andreas; Loonis, Roman; Roy, Jefferson E et al. (2018) Different Levels of Category Abstraction by Different Dynamics in Different Prefrontal Areas. Neuron 97:716-726.e8|
|Fan, Xin; Xie, Bobo; Zou, Jun et al. (2018) Novel ETFDH mutations in four cases of riboflavin responsive multiple acyl-CoA dehydrogenase deficiency. Mol Genet Metab Rep 16:15-19|
Showing the most recent 10 out of 867 publications